If you have been reading about immunomodulator and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-02. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Reconstituted before use |
| Typical storage | 2-8 °C, protected from light | Applies to the powder |
| Reconstitution solvent | Sterile water or saline | Follow product labeling |
| Solution stability | Shorter than the powder | Refrigerate and use promptly |
| Primary purity method | Reversed-phase HPLC | Detects related substances |
Methane clumped isotopes are methane molecules that contain two or more rare isotopes. Methane (CH4) contains two elements, carbon and hydrogen, each of which has two stable isotopes. For carbon, 98.9% are in the form of carbon-12 (12C) and 1.1% are carbon-13 (13C); while for hydrogen, 99.99% are in the form of protium (1H) and 0.01% are deuterium (2H or D). Carbon-13 (13C) and deuterium (2H or D) are rare isotopes in methane molecules. The abundance of the clumped isotopes provides information independent from the traditional carbon or hydrogen isotope composition of methane molecules.
Levobunolol (trade names AKBeta, Betagan, Vistagan, among others) is a non-selective beta blocker. It is used topically in the form of eye drops to manage ocular hypertension (high pressure in the eye) and open-angle glaucoma.
== Distribution == Aristotelia chilensis is native to Chile and Argentina near the southwest coast of South America. It is found naturally in Chilean rainforests. Its native range spans the area between the Coquimbo and Aysén regions of Chile, and is 170,000 hectares (420,000 acres) in total.
In 1955, Harry Winokur worked with brother-in-law William Rosenberg, the founder of Dunkin' Donuts. After Winokur broke his partnership with Rosenberg, he went on to create Mister Donut with his son-in-law, David Slater that same year, with stores in most of North America. The Mister Donut business became so popular that Winokur and Slater decided to go into franchising. As a result, Mister Donut began a rapid expansion that resulted in the opening of 275 stores in the U.S. and Canada. In 1970, Minneapolis-based International Multifoods Corporation, one of the world's largest and most successful food companies, acquired Mister Donut and its franchising concept from Winokur. The first Mister Donut outlet in Japan opened in Minoh, Osaka in 1971. Also in the same year, a Mister Donut training center was constructed in Japan. In 1973, the French cruller became available in Japanese stores. In 1978, brothers Sutthichai and Sutthikiat Chirathiwat, on behalf of Thai Franchise Co., Ltd, opened the first Mister Donut store in Siam Square, Bangkok. The two would come to pioneer the donut market within Thailand. In 2003, Mister Donut in Thailand came under the management of CRG. Donut Thailand (Central Restaurants Group) which continues to manage the company in Thailand. In 1983, Duskin Co., Ltd. of Osaka, Japan, acquired the rights to franchise Mister Donut throughout Japan and Asia.
Heterodimerization with ERAP2 Some experimental evidence has indicated the possibility of heterodimer formation between ERAP1 and ERAP2, another member of the oxytocinase sub-family of M1 aminopeptidases, that shares structural and functional similarities. The co-elution of ERAP1 and ERAP2 was detected through microsome fractionation, in the 230 kDa fraction, suggesting the formation of heterodimers. Proximity ligation assay analysis suggested a direct physical interaction between the two enzymes. A leucine zipper mediated ERAP1/ERAP2 complex exhibited enhanced trimming efficiency compared to a mixture of the two enzymes. Computational dynamics showed that ERAP1/ERAP2 heterodimerization could be mediated by the exon 10 loop, known to be involved in ERAP1-ERp44 interactions.
Sources: en.wikipedia.org
== Isomerism == Scientists discovered some substances have the exact same chemical content but different properties. For instance, in 1827, Friedrich Wöhler discovered that silver fulminate and silver cyanate are both 107 parts silver, 12 parts carbon, 14 parts nitrogen, and 16 parts oxygen (we now know their formulas as both AgCNO). In 1830 Jöns Jacob Berzelius introduced the term isomerism to describe the phenomenon. In 1860, Louis Pasteur hypothesized that the molecules of isomers might have the same set of atoms but in different arrangements. In 1874, Jacobus Henricus van 't Hoff proposed that the carbon atom bonds to other atoms in a tetrahedral arrangement. Working from this, he explained the structures of organic molecules in such a way that he could predict how many isomers a compound could have. Consider, for example, pentane (C5H12). In van 't Hoff's way of modelling molecules, there are three possible configurations for pentane, and scientists did go on to discover three and only three isomers of pentane.
Dicarbonyls react with amines to produce Strecker aldehydes through Strecker degradation. Acrylamide, a possible human carcinogen, can be generated as a byproduct of the Maillard reaction between reducing sugars and amino acids, especially asparagine, both of which are present in most food products.
1.1 L (1071 cc) E1, 1 barrel, 55 PS (40 kW; 54 hp) / 79 N⋅m (58 lb⋅ft) 1.3 L (1296 cc) E3, 2 barrel, 68 PS (50 kW; 67 hp) / 95 N⋅m (70 lb⋅ft) 1.5 L (1490 cc) E5, 2 barrel, 75 PS (55 kW; 74 hp) / 115 N⋅m (85 lb⋅ft) 1.5 L (1490 cc) E5S, 2x2 barrel, 88 PS (65 kW; 87 hp) / 120 N⋅m (89 lb⋅ft) The most powerful version was marketed as the "323 GT" in European markets. The Familia/323 underwent a facelift in January 1983. For the Japanese market other top end models were offered, originally the three-door Familia XGI with a 1,500 cc single cam, multi-point fuel-injected engine. In June 1983 the turbocharged XGI Turbo was added, Mazda's first turbocharged piston engine. It had a particularly small turbocharger, for better low-end response. Period commentators complimented its linear and smooth power delivery. The XG Turbo also received a suitably updated chassis and wheels to handle the 115 PS (85 kW). The Familia saloon and their twin, the Ford Laser S, was also offered with the same specifications but in limited numbers. Claimed outputs in the Japanese market were considerably higher than in export countries, due to the differing JIS standard rather than DIN. Period sources suggest subtracting ten percent from the JIS numbers. This particular Familia was a strong comeback for Mazda in the Japanese market, even outselling the Toyota Corolla on several occasions. The four-door saloon was equipped with a reverse-rake front grille and lights in the Japanese market, to make it appear more "senior". The same front design was used for the GA/GB Ford Meteor.
=== Trial and conviction === On May 10, 2010, a three-week trial commenced where Second Circuit District judge John F. Keenan presided. The trial concluded on June 4 when the jury returned a guilty verdict on all five counts, albeit, guilty on a lesser charge of aiding and abetting rather than running a sanctions violation money transmittal system. On June 7, 2010, despite the superseding indictment charge of $3.4 million, the same jury agreed to forfeit one bank account associated with a $6,000 transaction as the proceeds of the charges and the guilty verdict. The jury ruled that Mahmoud Reza Banki's other assets including the apartment he had purchased with the family funds he had received was not a direct proceeds of any crime and not forfeitable. Judge Keenan overruled the jury only in the case of the forfeiture verdict on the basis that the jury might have been "confused" and awarded the government prosecutors a money judgment order, essentially ignoring the jury verdict on forfeiture and awarding the US Attorney's office $3.4 million, to be paid by Banki. This would have been the same as if the jury had come to the decision of full forfeiture of all of Banki's assets.
== Murders and assaults == While she was a nurse at Caressant Care, Wettlaufer began injecting some of the patients she cared for with insulin. In some cases, the amount was not enough to kill the patient; she was charged with, and confessed to, aggravated assault or attempted murder for those cases. Wettlaufer's first assaults occurred sometime between June 25 and December 31, 2007. She confessed that she injected sisters Clotilde Adriano (age 87) and Albina Demedeiros (88) with insulin. While they later died, their deaths were not attributed to Wettlaufer. She confessed to two counts of aggravated assault. The first case in which Wettlaufer injected a patient with enough insulin to directly cause death was on August 11, 2007, when she murdered James Silcox (84), a World War II veteran and father of six. From 2007 to March 2014, Wettlaufer also murdered the following patients at Caressant Care:
Sources: en.wikipedia.org
=== EC 1.14.16 With reduced pteridine as one donor, and incorporation of one atom of oxygen into the other donor === EC 1.14.16.1: phenylalanine 4-monooxygenase EC 1.14.16.2: tyrosine 3-monooxygenase EC 1.14.16.3: withdrawn owing to insufficient evidence (anthranilate 3-monooxygenase) EC 1.14.16.4: tryptophan 5-monooxygenase EC 1.14.16.5: alkylglycerol monooxygenase EC 1.14.16.6: mandelate 4-monooxygenase EC 1.14.16.7: phenylalanine 3-monooxygenase
== Prognosis == Patient response to treatment will vary based on age, health, and the tolerance to medications and therapies. Metastasis occurs in about 39% of patients, most commonly to the lung. Features associated with poor prognosis include a large primary tumor (over 5 cm across), high grade disease, co-existent neurofibromatosis, and the presence of metastases. It is a rare tumor type, with a relatively poor prognosis in children. In addition, MPNSTs are extremely threatening in NF1. In a 10-year institutional review for the treatment of chemotherapy for MPNST in NF1, which followed the cases of 1 per 2,500 in 3,300 live births, chemotherapy did not seem to reduce mortality, and its effectiveness should be questioned. Although with recent approaches with the molecular biology of MPNSTs, new therapies and prognostic factors are being examined.
Tramadol is used primarily to treat mild to severe pain, both acute and chronic. There is moderate evidence for use as a second-line treatment for fibromyalgia, but it is not FDA-approved for this use. Its use is approved for treatment of fibromyalgia as a secondary painkiller by the UK NHS. Its analgesic effects take approximately an hour to be realized, and it takes from two to four hours to reach peak effect after oral administration with an immediate-release formulation. On a dose-by-dose basis, tramadol has about one-tenth the potency of morphine (thus 100 mg is commensurate with 10 mg morphine but may vary) and is practically equally potent when compared with pethidine and codeine. For moderate pain, its effectiveness is roughly equivalent to that of codeine in low doses and hydrocodone at very high doses. For severe pain, it is less effective than morphine. Pain-reducing effects last approximately six hours. The potency of analgesia varies considerably as it depends on an individual's genetics. People with specific variants of CYP2D6 enzymes may not produce adequate amounts of the active metabolite (desmetramadol) for effective pain control.
Subcutaneous administration of parathyroid hormone into the abdomen produces a rapid increase in plasma parathyroid hormone levels which reach peak at 1 to 2 hours after dosing. The mean half-life is approximately 1.5 hours. The absolute bioavailability of 100 micrograms of Preotact after subcutaneous administration in the abdomen is 55%.
Sources: en.wikipedia.org
The lyophilized powder is kept refrigerated at 2 to 8 degrees Celsius and protected from light. Reconstituted solutions should be used promptly. Freezing and thawing repeatedly is avoided.
Reversed-phase HPLC is the primary tool for purity, paired with mass spectrometry for identity. Amino acid analysis and peptide mapping add sequence confirmation. Several techniques are combined because no single test covers every attribute.
It lacks sulfur-containing residues, so oxidation is limited. Aspartate isomerization and slow hydrolysis are the main concerns. Solution stability is shorter than that of the lyophilized powder.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.